Bionano Genomics reported a quarterly loss of $0.76 per share, better than the Zacks Consensus Estimate for a $0.81 loss and improved from a $1.15 loss a year ago. The result is a modest earnings beat and year-over-year improvement, though the company remains loss-making. The article provides no revenue or guidance details, so market impact is likely limited.
Bionano Genomics reported a quarterly loss of $0.76 per share, better than the Zacks Consensus Estimate for a $0.81 loss and improved from a $1.15 loss a year ago. The result is a modest earnings beat and year-over-year improvement, though the company remains loss-making. The article provides no revenue or guidance details, so market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.22
Ticker Sentiment
